Arbutus Biopharma Corp. Company Profile (NASDAQ:ABUS)

About Arbutus Biopharma Corp.

Arbutus Biopharma Corp. logoArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ABUS
  • CUSIP:
Key Metrics:
  • Previous Close: $3.66
  • 50 Day Moving Average: $3.99
  • 200 Day Moving Average: $3.98
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.88
  • P/E Growth: 0.00
  • Market Cap: $202.20M
  • Outstanding Shares: 54,796,000
  • Beta: 1.26
Additional Links:
Companies Related to Arbutus Biopharma Corp.:

Analyst Ratings

Consensus Ratings for Arbutus Biopharma Corp. (NASDAQ:ABUS) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $9.96 (169.87% upside)

Analysts' Ratings History for Arbutus Biopharma Corp. (NASDAQ:ABUS)
Show:
DateFirmActionRatingPrice TargetDetails
8/21/2016William BlairReiterated RatingOutperformView Rating Details
8/17/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
8/5/2016WedbushReiterated RatingOutperform$13.00 -> $20.00View Rating Details
7/8/2016Chardan CapitalDowngradeNeutral -> Sell$3.25 -> $2.75View Rating Details
12/21/2015Royal Bank Of CanadaLower Price Target$20.00 -> $12.00View Rating Details
9/2/2015JMP SecuritiesInitiated CoverageOutperform$13.00View Rating Details
6/16/2015Maxim GroupLower Price TargetHold -> Buy$27.00 -> $14.00View Rating Details
3/30/2015NomuraInitiated CoverageBuy$32.00View Rating Details
11/7/2014Stifel NicolausReiterated RatingPositive -> Buy$31.00 -> $26.00View Rating Details
(Data available from 8/29/2014 forward)

Earnings

Earnings History for Arbutus Biopharma Corp. (NASDAQ:ABUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q2($0.39)($0.75)ViewN/AView Earnings Details
5/4/2016Q1($0.39)($0.19)ViewN/AView Earnings Details
3/9/2016Q4($0.41)($0.06)ViewN/AView Earnings Details
11/5/2015($0.31)($0.42)ViewN/AView Earnings Details
8/5/2015Q2($0.26)($0.20)ViewN/AView Earnings Details
3/13/2015($0.32)($0.27)ViewN/AView Earnings Details
11/6/2014Q314($0.31)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details
8/13/2014Q214($0.26)($0.28)$3.72 million$1.80 millionViewN/AView Earnings Details
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arbutus Biopharma Corp. (NASDAQ:ABUS)
Current Year EPS Consensus Estimate: $-1.86 EPS
Next Year EPS Consensus Estimate: $-1.96 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.38)($0.36)($0.37)
Q2 20162($0.40)($0.35)($0.38)
Q3 20162($0.41)($0.39)($0.40)
Q4 20162($0.39)($0.36)($0.38)
Q1 20171($0.66)($0.66)($0.66)
Q2 20171($0.69)($0.69)($0.69)
Q3 20171($0.71)($0.71)($0.71)
Q4 20171($0.73)($0.73)($0.73)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arbutus Biopharma Corp. (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Arbutus Biopharma Corp. (NASDAQ:ABUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Arbutus Biopharma Corp. (NASDAQ:ABUS)
DateHeadline
seekingalpha.com logoTracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2016 Update (NASDAQ:ABUS)
seekingalpha.com - August 22 at 8:03 AM
4-traders.com logoARBUTUS BIOPHARMA CORP : Entry into a Material Definitive Agreement (form 8-K) (NASDAQ:ABUS)
www.4-traders.com - August 20 at 3:17 PM
bizjournals.com logoMajor tenant leaving Pa. Biotechnology Center for more space in Warminster (NASDAQ:ABUS)
www.bizjournals.com - August 19 at 8:16 PM
News IconCrowd is Weighing in on Arbutus Biopharma Corp (NASDAQ:ABUS) - Post News (NASDAQ:ABUS)
www.kentuckypostnews.com - August 17 at 3:16 PM
capitalcube.com logoArbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:ABUS)
www.capitalcube.com - August 15 at 3:17 PM
finance.yahoo.com logoShould You Get Rid of Arbutus Biopharma (ABUS) Now? (NASDAQ:ABUS)
finance.yahoo.com - August 12 at 11:48 AM
fortune.com logoAnalysts Downgrades Report: Arbutus Biopharma Corp (NASDAQ:ABUS) - Review Fortune (NASDAQ:ABUS)
reviewfortune.com - August 10 at 11:49 AM
finance.yahoo.com logo4:35 pm Arbutus Biopharma announces the issuance of a new patent for its proprietary lipid nanoparticle delivery technology (NASDAQ:ABUS)
finance.yahoo.com - August 8 at 8:43 PM
publicnow.com logoArbutus Announces Issuance of Broad New US Patent for LNP Delivery Technology (NASDAQ:ABUS)
www.publicnow.com - August 8 at 8:43 PM
sg.finance.yahoo.com logoArbutus reports 2Q loss (NASDAQ:ABUS)
sg.finance.yahoo.com - August 5 at 11:37 AM
publicnow.com logoArbutus Provides Corporate Update and Announces Second Quarter 2016 Financial Results (NASDAQ:ABUS)
www.publicnow.com - August 4 at 8:58 PM
kcregister.com logoKinder Morgan, Inc. (NYSE:KMI) rose 0.54%: Arbutus Biopharma Corporation (NASDAQ:ABUS), BCE Inc. (NYSE:BCE ... - KC Register (NASDAQ:ABUS)
www.kcregister.com - August 1 at 3:15 PM
kcregister.com logoArbutus Biopharma Corporation (NASDAQ:ABUS) fell -2.61%, International Business Machines Corporation (NYSE ... - KC Register (NASDAQ:ABUS)
www.kcregister.com - July 27 at 3:18 PM
News IconArbutus Biopharma Corp (NASDAQ:ABUS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:ABUS)
www.engelwooddaily.com - July 22 at 11:25 AM
News IconEquity Roundup: Stock Performance Focus on Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph (NASDAQ:ABUS)
presstelegraph.com - July 21 at 3:15 PM
fiscalstandard.com logoBroker Outlook For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Fiscal Standard (NASDAQ:ABUS)
www.fiscalstandard.com - July 21 at 11:29 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Arbutus Biopharma Corp (NASDAQ:ABUS) - TGP (NASDAQ:ABUS)
telanaganapress.com - July 20 at 11:24 AM
streetinsider.com logoArbutus Biopharma (ABUS) Says TKM-PLK1 Well-Tolerated in Phase I/II Trial - StreetInsider.com (NASDAQ:ABUS)
www.streetinsider.com - July 20 at 11:24 AM
4-traders.com logoArbutus Reports Topline Results from TKM-PLK1 HCC Clinical Trial (NASDAQ:ABUS)
www.4-traders.com - July 19 at 8:42 PM
News IconArbutus Biopharma Corporation (NASDAQ:ABUS) Shorted Shares Decreased By 8.15% - Consumer Eagle (NASDAQ:ABUS)
www.consumereagle.com - July 16 at 3:15 PM
News IconAnalyst Target and Average Rating Watch: Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph (NASDAQ:ABUS)
presstelegraph.com - July 15 at 7:30 PM
News IconArbutus Biopharma Corp (NASDAQ:ABUS) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:ABUS)
www.engelwooddaily.com - July 15 at 7:30 PM
News IconTrading Performance and Target Watch for Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph (NASDAQ:ABUS)
presstelegraph.com - July 14 at 8:44 PM
finance.yahoo.com logoAndreas Halvorsen's Viking Global Gets Control of Stakes in 2 Companies for Backing Hot Biotech (NASDAQ:ABUS)
finance.yahoo.com - July 14 at 7:20 PM
News IconChardan Capital Downgrades Arbutus Biopharma Corp to Sell - TheFounders Daily (NASDAQ:ABUS)
www.thefoundersdaily.com - July 14 at 3:15 PM
news.cmlviz.com logoArbutus Biopharma Corporation Realized Volatility Hits Extreme Level - CML News (NASDAQ:ABUS)
news.cmlviz.com - July 14 at 3:15 PM
finance.yahoo.com logoRoivant Sciences Appoints Professor Andrew Lo, PhD as Independent Director (NASDAQ:ABUS)
finance.yahoo.com - July 13 at 4:01 PM
News IconArbutus Biopharma Corp (NASDAQ:ABUS) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:ABUS)
telanaganapress.com - July 12 at 8:44 PM
News IconStock Rating Watch and Earnings Insight for Arbutus Biopharma Corp (NASDAQ:ABUS) - Press Telegraph (NASDAQ:ABUS)
presstelegraph.com - July 11 at 8:02 AM
fiscalstandard.com logoArbutus Biopharma Corporation (NASDAQ:ABUS) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:ABUS)
www.fiscalstandard.com - July 10 at 3:15 PM
News IconArbutus Biopharma Corporation (NASDAQ:ABUS) Sellers Covered 8.15% of Their Shorts - Press Telegraph (NASDAQ:ABUS)
presstelegraph.com - July 9 at 11:22 AM
News IconCompany Stock Focus for Arbutus Biopharma Corp (NASDAQ:ABUS): Which Way Will Shares Head? - Press Telegraph (NASDAQ:ABUS)
presstelegraph.com - July 8 at 3:16 PM
news.cmlviz.com logoArbutus Biopharma Corporation Stock Momentum at Critical Inflection Point - CML News (NASDAQ:ABUS)
news.cmlviz.com - July 7 at 3:15 PM
News IconArbutus Biopharma Corp (NASDAQ:ABUS) Stock Update: Check on Ratings and Target Price - Telanagana Press (NASDAQ:ABUS)
telanaganapress.com - July 6 at 8:02 AM
kcregister.com logoEye Catching Stocks: Arbutus Biopharma Corporation (NASDAQ:ABUS), Facebook Inc (NASDAQ:FB), Organovo ... - KC Register (NASDAQ:ABUS)
www.kcregister.com - July 5 at 8:02 AM
News IconDoes Arbutus Biopharma Corp Have Any Gas After Today's Huge Increase? - Press Telegraph (NASDAQ:ABUS)
presstelegraph.com - July 4 at 3:15 PM
News IconArbutus Biopharma Corp (NASDAQ:ABUS) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:ABUS)
www.engelwooddaily.com - July 1 at 8:29 PM
News IconCovering the Bases on Arbutus Biopharma Corp (NASDAQ:ABUS): Where is the Stock Going? - Press Telegraph (NASDAQ:ABUS)
presstelegraph.com - July 1 at 8:29 PM
ftsenews.co.uk logoArbutus Biopharma Corporation (NASDAQ:ABUS) Updated Price Targets - FTSE News (NASDAQ:ABUS)
www.ftsenews.co.uk - July 1 at 3:15 PM
twst.com logoTekmira Pharmaceuticals Corporation: Arbutus to Present mRNA Delivery Data at the 32nd Annual Meeting of the ... - The Wall Street Transcript (NASDAQ:ABUS)
www.twst.com - June 30 at 3:15 PM
biz.yahoo.com logoARBUTUS BIOPHARMA CORP Files SEC form 8-K, Other Events (NASDAQ:ABUS)
biz.yahoo.com - June 30 at 8:01 AM
finance.yahoo.com logoArbutus to Present mRNA Delivery Data at the 32nd Annual Meeting of the Japan Society of Drug Delivery System (NASDAQ:ABUS)
finance.yahoo.com - June 30 at 8:00 AM
fiscalstandard.com logoRecently Issued Stock Ratings For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Fiscal Standard (NASDAQ:ABUS)
www.fiscalstandard.com - June 29 at 3:14 PM
News IconArbutus Biopharma Corporation (NASDAQ:ABUS) Sellers Covered 8.15% of Their Shorts - Engelwood Daily (NASDAQ:ABUS)
www.engelwooddaily.com - June 29 at 11:10 AM
News IconChardan Capital Upgrades Arbutus Biopharma Corp to Neutral with Price Target $3.25 - TheFounders Daily (NASDAQ:ABUS)
www.thefoundersdaily.com - June 25 at 11:19 AM
ftsenews.co.uk logoNew Broker Ratings For Arbutus Biopharma Corporation (NASDAQ:ABUS) - FTSE News (NASDAQ:ABUS)
www.ftsenews.co.uk - June 24 at 11:12 AM
fiscalstandard.com logoThis Weeks Broker Views For Arbutus Biopharma Corporation (NASDAQ:ABUS) - Fiscal Standard (NASDAQ:ABUS)
www.fiscalstandard.com - June 20 at 3:15 PM
biz.yahoo.com logoARBUTUS BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:ABUS)
biz.yahoo.com - June 8 at 12:20 PM
publicnow.com logoArbutus to Present at the 5th Antiviral Drugs Research and Development Conference (NASDAQ:ABUS)
www.publicnow.com - June 1 at 8:03 AM
News IconIs Selling Stock Like Arbutus Biopharma Corp After Such Decline Winning Strategy? - HNN (NASDAQ:ABUS)
hintsnewsnetwork.com - May 28 at 11:37 AM

Social

Arbutus Biopharma Corp. (NASDAQ:ABUS) Chart for Monday, August, 29, 2016


Last Updated on 8/29/2016 by MarketBeat.com Staff